Celebrating Wild Caraway: Taste of Nova Scotia's Restaurant of the Year | SaltWire - U.S. companies across sectors such as food and beverage makers and manufacturers of glucose monitors are facing investor questions over the risk to future sales from the growing popularity of promising weight-loss treatments.
Mounjaro, which uses the same active ingredient, was approved for diabetes patients last year, but some consumers were using it off-label for weight loss.Conagra might consider changing portion sizes of its snacks if the rising use of weight-loss drugs leads to a change in food consumption patterns. Coca-Cola CEO James Quincey said the company was monitoring what impact, if any weight-loss drugs will have.
Davita is closely monitoring developments related to the drug and expects limited impact from use of the drugs, since they may only benefit some kidney disease patients.Johnson & Johnson's third-quarter sales for devices used in abdomen surgeries was hit by a slowdown in demand for weight-loss and other procedures, as many obese patients turned to Wegovy and Ozempic.
Abbott CEO Robert Ford has said diabetes patients could end up using glucose monitors with the weight-loss drugs in the long term. Dexcom, which also makes such monitors, said something similar in late October.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
La source: YahooFinanceCA - 🏆 47. / 63 Lire la suite »
La source: YahooFinanceCA - 🏆 47. / 63 Lire la suite »